Holista Colltech Limited (ASX:HCT): How Did Supplements Sales and Litigation Costs Affect Its Half-Year Result?

Aditi Sarkar

29 October 2026 05:09 PM AEDT

Holista Colltech Limited (ASX:HCT): How Did Supplements Sales and Litigation Costs Affect Its Half-Year Result?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

HCT shares changed hands at A$0.037 on 29 October 2026, with the daily move unchanged. The article reviews half-year revenue, gross margin, supplements sales, the reported loss and resolution of the ProImmune matter.
Supplements sales rose 12.2% to A$2.91 million.
The group reported a A$2.56 million loss, including about A$2.66 million in one-off costs related to the ProImmune settlement.

Holista Colltech Limited (ASX:HCT) operates within the health and wellness market and reported results and operating developments across its latest disclosure period.. As of 29 October 2026, HCT shares were priced at A$0.037, unchanged on the day. H1 FY26 revenue grew 3.6% to A$2.99 million, with gross margin reaching 44.3%. The article reviews half-year revenue, gross margin, supplements sales, the reported loss and resolution of the ProImmune matter.

Revenue, margin and net result

Holista Colltech reported revenue of A$2.99 million for the six months ended 30 June 2026, up 3.6% from A$2.89 million in H1 FY25. Gross profit increased to approximately A$1.33 million from A$1.21 million, and gross margin rose to 44.3% from 41.9%. The group recorded a A$2.56 million net loss compared with A$0.30 million in the prior corresponding half. The results included a significant litigation-related cost.

Supplements performance

Dietary Supplements contributed A$2.91 million in revenue, up 12.2% on H1 FY25. Holista cited broader marketplace distribution, changes to its sales and marketing capabilities and a favourable A$128,000 adjustment to refund liabilities. The company launched a refreshed e-commerce website and expanded into TikTok Shop during the period. It also outlined anniversary-related marketing for its Pristin brand. This business represented most of group revenue for the half year.

Other divisions and product work

The Food Ingredients division recorded A$29,963 in revenue, compared with A$204,889 in H1 FY25, as its largest customer adopted a more conservative approach to inventory. Ovine Collagen revenue was A$28,781 against A$90,394 a year earlier after closure of its former Collie facility. The Infection Control and Agriculture division recorded A$23,484 of revenue. Management outlined product development in low-sugar ingredients and continued trials of agriculture-related products.

ProImmune settlement and financing

The company settled the ProImmune dispute for US$1.8 million, with the final payment completed in July 2026. Holista attributed approximately A$2.66 million in one-off costs to the matter in its H1 FY26 result. Excluding that amount, it reported an approximate underlying after-tax profit of A$95,000. The company also entered into a conditional convertible-loan agreement for A$370,724 at an annual interest rate of 8%, with conversion subject to shareholder approval.

Collagen project and next steps

Holista reported progress on the ovine collagen joint venture with Swang Chai Chuan Limited. A contribution of RM5.0 million from the partner supported acquisition of land in Collie, Western Australia, for a proposed manufacturing operation. Planning and implementation remained under way. In addition, the group said its agriculture business was seeking repeat orders following initial product trials. These corporate initiatives were disclosed separately from the six-month financial figures.

Key Insights

Holista Colltech reported higher half-year revenue, gross profit and gross margin, supported by its supplements business. Its statutory net loss included costs associated with the ProImmune settlement, while the company also disclosed developments across food ingredients, collagen and agriculture.

FAQs

Q: What was Holista’s H1 FY26 revenue?

A: A$2.99 million, up 3.6%.

Q: What was the reported net result?

A: A A$2.56 million net loss.

Q: How much was the ProImmune settlement?

A: US$1.8 million.

Q: How much did gross margin improve?

A: Gross margin increased to 44.3% from 41.9% in the prior corresponding half-year.

Q: What was the underlying result excluding settlement costs?

A: The company reported approximately A$95,000 in underlying profit after tax after excluding specified settlement-related costs.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.